Showing results (91-100 of 122) with videos related to
Sort By:
Pageof 13
European Journal of Cancer (Oxford, England : 1990)|February 5, 2000
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCORT André, C Louvet, F Maindrault-Goebel, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2013
Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trialF C Bidard, F Huguet, C Louvet, et al.Critical Reviews in Oncology/Hematology|June 18, 2011
Disseminated and circulating tumor cells in gastrointestinal oncologyF C Bidard, F R Ferrand, F Huguet, et al.International Journal of Radiation Oncology, Biology, Physics|March 8, 2000
Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility studyT André, J Balosso, C Louvet, et al.European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST)S Watson, C de la Fouchardière, S Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trialC Louvet, R Labianca, P Hammel, et al.European Journal of Cancer (Oxford, England : 1990)|February 5, 2000
Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCORF Maindrault-Goebel, C Louvet, T André, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimenT André, M A Bensmaine, C Louvet, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2009
Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatinA Zaanan, P Cuilliere-Dartigues, A Guilloux, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2002
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patientsC Louvet, T André, J M Tigaud, et al.Pageof 13